Latest Breaking News On - Sandra silberman - Page 1 : comparemela.com

Form 8-K CNS Pharmaceuticals, For: Dec 21

Form 8-K CNS Pharmaceuticals, For: Dec 21
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSandra silbermanJohn climcaoSecurities exchangeCommission file numberStock marketPharmaceuticals incExchange actLoop southZip codeFormer nameFormer addressChanged since last reportGeneral instructionSecurities actSecurities exchange act

How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure - CNS Pharma (NASDAQ:CNSP)

Every form of cancer is devastating, but the unfortunate reality is not all cancers are created equal. There are certain forms that are more deadly, with Glioblastoma (GBM) being one of the worst. GBM is a highly aggressive type of brain cancer with no cure, leading to a grim prognosis and average survival time of only 14 to 16 months.

United statesJohn climacoJohn mccainTed kennedySandra silbermanPharmaceuticals incSenators john mccainDifferent approachOverall survivalChief medical officerOlga kononenko

CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from

CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from .

United statesBritish columbiaSandra silbermanSociety of neurooncologyReata pharmaceuticals incPharmaceuticals fast track designation for berubicinUniversity of texas md anderson cancer centerNews networkPharmaceuticals incCompany on twitterSecurities exchangePresents updated safety dataAnnual meetingGlioblastoma multiformeChief medical officerInterim results

CNS Pharmaceuticals, Inc : CNS Pharmaceuticals Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy

CNS Pharmaceuticals, Inc : CNS Pharmaceuticals Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Rheinland pfalzBritish columbiaUnited statesJenene thomasSandra silbermanPharmaceuticals incSecurities exchangePharmaceuticals fast track designation for berubicinReata pharmaceuticals incUniversity of texas md anderson cancer centerCompany on twitterSociety of neurooncologyExchange commissionPharmaceuticals inc viewGlioblastoma multiformeAnnual meeting

CNS Pharmaceuticals (CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy

CNS Pharmaceuticals (CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

British columbiaSandra silbermanPharmaceuticals fast track designation for berubicinCns pharmaceuticals incAnnual meetingChief medical officerInterim resultsUpdated safety resultsPotentially pivotal studyKarnofsky performance status scaleOverall survivalData safety monitoring boardFast track designationOrphan drug designation